The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The rising prevalence of cardiovascular disorders is likely to stimulate innovation in the production of hypertrophic cardiomyopathy HCM therapies, propelling the market during the forecast period.

The global hypertrophic cardiomyopathy HCM therapeutics market is expected to grow from $1.26 billion in 2022 to $1.30 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The global hypertrophic cardiomyopathy (HCM) therapeutics market size is expected to reach $1.43 billion in 2027 at a CAGR of 2.4%.

Get A Free Sample On The Global Hypertrophic Cardiomyopathy HCM Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9914&type=smp

Global Hypertrophic Cardiomyopathy HCM Therapeutics Market Segments Include:

• By Drug Type: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types
• By Device Type: Defibrillators, Pacemakers, Other Device Types
• By End User: Hospitals, Clinics
• By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America is the largest region in the global hypertrophic cardiomyopathy HCM therapeutics market in 2021.

Major Market Players in the hypertrophic cardiomyopathy HCM therapeutics market include Merck & Co. Inc, Pfizer Inc, Sanofi S.A., Teva Pharmaceutical Industries Ltd, Novartis AG, Astra Zeneca Plc, Gilead Sciences Inc, Bayer AG, Correvio Pharma Corp.

The primary trend gaining traction in the hypertrophic cardiomyopathy (HCM) therapies market is product innovation. Major firms in the cardiomyopathy therapeutics sector are focusing on developing new novel products to increase their market position. For example, Bristol Myers Squibb, a biopharmaceutical firm based in the United States, released Camzyos (mavacamten) in April 2022, an oral small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) and illnesses of heart diastolic failure. The US Food and Drug Administration (FDA) licenced Camzyos (mavacamten) for the treatment of people with symptomatic class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to enhance functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible cardiac myosin inhibitor that tackles the underlying pathology of obstructive HCM. Camzyos regulates how many myosin heads can enter “on actin” (power-generating) states.

The Hypertrophic Cardiomyopathy HCM Therapeutics Global Market Report 2023 provides a hypertrophic cardiomyopathy HCM therapeutics market overview for the time series: historic years (2010 – 2021) and ten years forecast (2023 – 2032). The hypertrophic cardiomyopathy HCM therapeutics market forecast analyzes hypertrophic cardiomyopathy HCM therapeutics market size, hypertrophic cardiomyopathy HCM therapeutics market share, leading competitor market positions. The regions covered in the report include Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa and the countries include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The therapy of hypertrophic cardiomyopathy (HCM) is a disorder in which the heart muscle becomes abnormally thick or hypertrophied. The thickening of the cardiac muscle causes the heart to become ineffective at pumping blood. Therapeutics for hypertrophic cardiomyopathy (HCM) attempt to decrease symptoms and protect against sudden cardiac death in high-risk patients.

Explore Similar Reports From The Business Research Company:

Gardner Syndrome Treatment Global Market Report 2023

Neurodegenerative Disorder Therapeutics Global Market Report 2023

Antisense & RNAi Therapeutics Global Market Report 2023

Learn More About The Business Research Company
The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: